Legal Representation
Attorney
Nancy Sabarra
USPTO Deadlines
Next Deadline
1138 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20230314)
Due Date
March 14, 2029
Grace Period Ends
September 14, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 22, 2023 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Jun 27, 2023 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Jun 27, 2023 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Jun 14, 2023 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Mar 14, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 14, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 27, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 27, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 7, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 21, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 21, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Nov 21, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Nov 21, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Nov 21, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Oct 21, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 21, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 21, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 10, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Apr 21, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Apr 21, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Apr 20, 2022 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Apr 19, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 19, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 11, 2022 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jan 7, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 6, 2022 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes in the form of a liquid solution or lyophilised preparation for therapeutic use for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations, namely, exosomes to deliver protein or nucleic acids or viral vectors for genetic therapy; medicine for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; Medical preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for medical purposes for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; biological preparations comprising exosome for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations comprising a therapeutic target protein-loaded, nucleic acid-loaded or virus-loaded exosome for the treatment of genetic diseases, respiratory diseases, or cancer; biological reagents for medical use; biological preparations for medical purposes, namely, for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; mixed biological preparations for the prevention and treatment of infectious diseases; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, EV-based nucleic acid therapeutic agents for the prevention and treatment of infections or disease; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint/ligament strain/tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific research and analysis services; biological research; clinical research in the field of transformational therapeutics; providing medical and scientific research information in the field of filtration of exosomes from cultured cells or blood; scientific investigations for medical purposes; scientific laboratory services; medical laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; information, advisory and consultancy services relating to the aforesaid, namely, scientific, medical and pharmaceutical research and development services, pharmaceutical drug development services, research and development of pharmaceutical preparations, scientific research and analysis services, biological research, clinical research in the field of transformational therapeutics, providing medical and scientific research information in the field of filtration of exosomes from cultured cells or blood, scientific investigations for medical purposes, scientific laboratory services, medical laboratory services, laboratory research services relating to pharmaceuticals, research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders, biotechnology, pharmaceutical research and development and genetic science, laboratory diagnostics, namely, medical analysis services relating to the diagnosis and treatment of persons provided by medical laboratories
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Medical services; medical and pharmaceutical consultancy; medical diagnostics, namely, medical testing, monitoring, and reporting services for diagnostic or treatment purposes; medical analysis services for the diagnosis and treatment of persons and for the diagnosis and treatment of genetic diseases; medical examination services; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; information, advisory and consultancy services relating to the aforesaid, namely, medical services, medical and pharmaceutical consultancy, medical diagnostics, namely, medical testing, monitoring, and reporting services, medical analysis services for the diagnosis and treatment of persons and for the diagnosis and treatment of genetic diseases, medical examination services, medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases, medical screening, medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases, and medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
EXO REPLACE
Classification
International Classes
005
042
044